Product Name: AurB (229-235) pT232
Product Number: PE-04AYQ00
Size: 200 µg      Price:8.00
1 mg      $US16.00
Peptide Name: AurB (229-235) pT232

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. T232 phosphorylation stimulates phosphotransferase activity and regulates cytoskeletal reorganization and intracellular location. Predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: RRK-pT-MCG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 930.04 Da

Peptide Purity Percent after Synthesis and Purification: < 50

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Scientific Background: AurB (AurKB, AIK2) is a protein-serine/threonine kinase of the Other group and AUR family. It serves as a component of the chromosomal passenger complex (CPC) that plays a critical role in regulating mitosis. AurB may be a tumour requiring protein (TRP). Its low rate of mutation and down-regulation in human cancers supports it identification as a tumour-requiring protein, and as a target for cancer drug development. However, AurB is overexpressed in some colorectal cancers and other tumour cell lines, which was thought to lead to multinuclearity, increased ploidy, and a predisposition to cancer. Through its dominant-negative effect on cytokinesis, disruptive regulation of its expression is potentially responsible for the perturbing the chromosomal integrity in cancer cells. A K106R mutation leads to loss of phosphotransferase activity, and severely impairs mitosis.